Cipla Q4 Results: Operating performance ex-impairment in-line with expectations; Stock jumps

Shares of drugmaker Cipla Ltd. gained as much as 3% after the company's results, reported on Wednesday, May 13, and adjusted for their impairment cost, were in-line with expectations for the January-March period.

Cipla's net profit fell 54.6% from the same quarter last year to ₹554.6 crore, lower than the CNBC-TV18 poll of ₹724 crore.

Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter declined 38% year-on-year to ₹955 crore, lower than the CNBC-TV18 poll of ₹1,034 crore. EBITDA was impacted due to an impairment cost of ₹42 crore during the quarter.

Adjusted for the impairment cost, Cipla's EBITDA would be ₹997 crore, largely in-line with expectations, and margins would be 15.2%, also in-line with the 15.3% projection.

Including the impairment cost, Cipla's EBITDA margin stood at 14.6% from 22.8% last year.

The Impairment Cost

During the quarter, Cipla had recorded an impairment of ₹42.02 crore with regards to associates, due to charges in certain business conditions and market dynamics.

Cipla's board has also approved a final dividend of ₹13 per share. The record date for this dividend payout has been fixed as June 5, 2026.

Shares of Cipla are now trading 2.8% higher at ₹1,328.5. The stock has risen 10% over the last one month.